Cat. No. 3578
Chemical Name: 5-(6-Quinoxalinylmethylene)-2,4-thi
Biological ActivityPotent and selective inhibitor of PI 3-kinase γ (PI 3-Kγ) (IC50 = 8 nM). Displays 30-fold selectivity over PI 3-Kδ and PI 3-Kβ and 7.5-fold selectivity over PI 3-Kα. Suppresses the progression of joint inflammation and damage in both lymphocyte-independent and lymphocyte-dependent mouse models of rheumatoid arthritis. Orally active and ATP-competitive.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Camps et al (2005) Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nature Med. 11 936.
Wang et al (2009) Phosphoinositide 3-kinase γ inhibitor ameliorates concanavalin A-induced hepatic injury in mice. Biochem.Biophys.Res.Comm. 386 569.
Peng et al (2010) Inhibition of phosphoinositide 3-kinase ameliorates dextran sodium sulfate-induced colitis in mice. J.Pharmacol.Exp.Ther. 332 46. PMID: 19828878.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: AS 605240, supplier, AS605240, PI3Kgamma, PI3Kγ, PI, 3-kinasegamma, 3-kinaseg, 3-kinaseγ, phosphoinositide, 3, kinases, gamma, γ, Potent, selective, inhibitors, inositol, lipids, signalling, signaling, orally, active, ATP-competitive
Find multiple products by catalog number
New Products in this Area
Glucokinase activatorMRT 67307 dihydrochloride
Salt inducible kinase (SIK) inhibitorLDN 209929 dihydrochloride
Potent and selective haspin kinase inhibitorRKI 1447 dihydrochloride
Potent and selective ROCK inhibitor; antitumorLIMKi 3
Potent LIM kinase inhibitor; antitumorFRAX 486
Potent p21-activated kinase (PAK) inhibitor; brain penetrant and orally bioavailableBIX 02189
Selective MEK5 and ERK5 inhibitorTC Mps1 12
Potent and selective monopolar spindle 1 (Mps1) kinase inhibitor; orally activeGSK 2606414
Potent and selective PERK inhibitor; orally bioavailableAZ 20
Potent and selective ATR kinase inhibitor; antitumorAZD 7762 hydrochloride
Potent and selective ATP-competitive inhibitor of Chk1 and Chk2PHT 427
Dual Akt and PDK1 inhibitor; antitumorML 786 dihydrochloride
Potent Raf kinase inhibitor; orally bioavailableSenexin A
Cyclin-dependent kinase 8 (cdk8) inhibitorXL 388
Potent and selective mTOR inhibitor; antitumorPS 1145 dihydrochloride
Selective IKK inhibitor; orally active
November 15 - 19, 2014
Washington D.C., USA